Candel Therapeutics, Inc. (CADL)
D
Pipeline Grade
Financial Position (from SEC Filings)
$195.3M
Cash & Equivalents
$18.0M
Quarterly Burn Rate
32 mo
Est. Cash Runway
$695M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase2 Readout | — |
Active Clinical Trials (7)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT01436968 | Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer | PHASE3 | Active Not Recruiting | 711 |
| NCT07660094 | Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrol... | PHASE3 | Recruiting | 500 |
| NCT02768363 | Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) | PHASE2 | Active Not Recruiting | 187 |
| NCT04495153 | CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC | PHASE2 | Active Not Recruiting | 90 |
| NCT07332000 | A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec | PHASE2 | Recruiting | 45 |
| NCT02446093 | Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma | PHASE2 | Active Not Recruiting | 54 |
| NCT03152318 | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 | PHASE1 | Active Not Recruiting | 62 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.